

Shionogi announces agreements on collaborative research with PharmaIN Corporation

OSAKA, Japan, January 10, 2018 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") has signed collaborative agreement with PharmaIN Corporation (Head Office: Bothell, WA; President and CEO; Elijah Bolotin, Ph.D.; hereafter "PharmaIN"). (The release by PharmaIN is [here](#).)

PharmaIN has unique drug delivery platform, called "Protected Graft Co-polymer" (PGC™) excipient and innovative peptide engineering technologies which can be applied to injectable peptide therapeutics. Besides peptides, PGC excipient can be beneficial to numerous proteins and some poorly soluble small molecules. Under the agreement with an exclusive two-year option to negotiate a license for the collaboration product, Shionogi will make an equity investment of up to \$17M USD in PharmaIN.

We believe a synergistic effect between Shionogi's strength in drug discovery in small and middle molecules and PharmaIN's unique platform technologies will make innovative therapeutics which are eagerly awaited by patients and medical personnel.

Shionogi has its vision, "Grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improving healthcare", and is striving to contribute to the better health and QOL of people all over the world by promoting open innovation with innovative companies such as PharmaIN in addition to our own R&D activities.

Contacts:

Corporate Communications, Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596